Why the study?
Omecamtiv mecarbil is an in vitro P-glycoprotein substrate and inhibitor, which can result in drug-drug interactions with agents such as digoxin and amiodarone.
Does coadministration of omecamtiv mecarbil with digoxin or amiodarone alter their pharmacokinetic profiles in healthy subjects?
Does coadministration of omecamtiv mecarbil with digoxin or amiodarone alter their pharmacokinetic profiles in healthy subjects?
Omecamtiv mecarbil can be safely coadministered with digoxin or amiodarone without clinically relevant pharmacokinetic drug-drug interactions or the need for dose adjustments.
Answers are grounded in this paper and cite their sources.
No clinically relevant DDI with digoxin or amiodarone; extends phase 1 data but leaves open confirmation in HFrEF patients.
Omecamtiv mecarbil (OM), a novel cardiac myosin activator, is being evaluated for the treatment of heart failure with reduced ejection fraction. In vitro studies demonstrate OM as a substrate and inhibitor of P-glycoprotein (P-gp), which can result in drug-drug interactions. Two phase 1, open-label studies assessed the effect of coadministration of OM (50-mg single dose) on the pharmacokinetics of digoxin (0.5-mg single dose; N = 15), a P-gp substrate, and the effect of coadministration of amiodarone (600-mg single dose), a P-gp inhibitor, on the pharmacokinetics of OM (50-mg single dose; N = 14) in healthy subjects. The ratios of the geometric least squares mean (90% confidence interval [CI]) of digoxin coadministered with OM vs digoxin alone for area under the plasma concentration-time curve (AUC) from time 0 to infinity, AUC from time 0 to the time of the last quantifiable concentration, and maximum observed plasma concentration were 1.06 (90%CI, 0.99-1.14), 1.06 (90%CI, 0.98-1.14), and 1.08 (90%CI, 0.92-1.26), respectively. The ratios of the geometric least squares mean of OM coadministered with amiodarone vs OM alone for AUC from time 0 to infinity, AUC from time 0 to the time of the last quantifiable concentration, and maximum observed plasma concentration were 1.21 (90%CI, 1.08-1.36), 1.21 (90%CI, 1.07-1.36), and 1.08 (90%CI, 0.96-1.22), respectively. In conclusion, OM coadministered with digoxin or amiodarone did not result in any clinically relevant pharmacokinetic drug-drug interactions.
No takes yet. Share an insight, caveat, or question.
Trivedi et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: